Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (7523)	10/23/1998 3:04:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

U.K. data for 40 weeks. Shows lab confirmed cases 40 th week were 33 while last year there were 24. For the year to the 40th week there have been 118 more cases. Too bad XOMA does not see fit to provide accrual rates for its' trials. phls.co.uk

To: Robert K. who wrote (7523)	10/26/1998 9:12:00 PM
From: Robert S.	Read Replies (2) \| Respond to of 17367

As always, Cacaito, appreciate your comments and the associated information. Robert K, one area of skepticism (regarding BPI) is the administration time-frame of this pharmaceutical compound. A study performed with rats (Jin, et al.,1995) revealed that BPI therapeutic efficacy decreases rapidly with respect to time of administration relative to contagion onset. Taking into account the accelerated physiological processes of rats, BPI given immediately or 30 minutes after LPS injection proved therapeutic but BPI given 2 hours after LPS injection produced no protective effect. In another study, this one with mice (Kelley, et al.,1993) BPI produced a 95% survival rate when administered immediately after E.coli inoculation but this survival rate decreased to 65% when 2 hours elapsed before BPI administration. Timing does indeed seem to be a critical issue and one has cause to ponder how efficacious BPI will be when utilized under uncontrolled "real world" conditions.